A5054377495- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Myasthenia Gravis and Thymoma
- Chronic Lymphocytic Leukemia Research
- Palliative Care and End-of-Life Issues
- Occupational and environmental lung diseases
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Pituitary Gland Disorders and Treatments
- Meningioma and schwannoma management
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cancer, Stress, Anesthesia, and Immune Response
- Polyomavirus and related diseases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Economic and Financial Impacts of Cancer
- Medical Imaging and Pathology Studies
- Pleural and Pulmonary Diseases
- Chronic Myeloid Leukemia Treatments
- Cancer Diagnosis and Treatment
Tokyo Metropolitan Komagome Hospital
2016-2025
Shikoku Cancer Center
2007
Kitasato University
2006-2007
Yokohama Municipal Citizen's Hospital
2000-2007
Abstract Background A history of pre-administration immune checkpoint inhibitors has been reported to be associated with good outcomes ramucirumab (RAM) plus docetaxel (DOC) combination therapy for advanced non-small-cell lung cancer (NSCLC). However, existing knowledge on the clinical significance RAM and DOC following combined chemoimmunotherapy is limited. Therefore, we evaluated efficacy safety after attempted identify predictors its outcomes. Patients Methods This multicenter,...
Stage IV non-small cell lung carcinoma (NSCLC) with oligometastases is potentially curable by radical treatment. This study aimed to evaluate the efficacy and safety of chemoradiotherapy (CRT) for thoracic disease, including primary lesion lymph node metastases, combined local consolidative therapy (LCT) oligometastases. was a multicenter Phase II trial patients NSCLC whom CRT disease feasible. The treatment procedures included containing platinum-doublet LCT within 8 weeks starting or...
Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Compared the clinical trials, real-world practice, osimertinib must be administered older those poor Eastern Cooperative Oncology Group performance status (ECOG-PS). Therefore, we investigated association between efficacy/safety PS score, age, other features NSCLC.We reviewed all NSCLC...
The safety of osimertinib is limited in patients with severe or moderate renal impairment, low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose (RD) epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) impaired function Thirty-one eligible were enrolled allocated into four cohorts: A, normal (estimated glomerular filtration rate [eGFR] ≥ 50 mL/min/1.73 m2 ) weight (≥45 kg); B, impairment (eGFR = 30-50 ); C, (<45...
Abstract Background In patients with non‐small cell lung cancer (NSCLC) harboring driver alterations, the efficacy of immune checkpoint inhibitors (ICIs) remains uncertain. Our study aimed to examine first‐line ICI in NSCLC KRAS , MET FGFR RET BRAF and HER2 alterations a real‐world setting. Methods This single‐center, retrospective cohort included advanced or driver‐negative, were treated therapy. Best overall response, progression‐free survival (PFS), (OS) evaluated. Results Seventy‐eight...
Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed durvalumab survival outcomes patients with locally advanced
Abstract Osimertinib is the standard of care for patients with epidermal growth factor receptor-activating mutation-positive non-small cell lung cancer. Dose-toxicity has been previously reported, but no dose–response data within range 20–240 mg daily (mg/d). Thus, current 80 mg/d dosing might be too high elderly Japanese an average body weight only 50 kg, resulting in excessive toxicity and cost. We therefore initiated a study to investigate whether osimertinib at 40 non-inferior advanced...
Pembrolizumab is a major treatment for recurrent or advanced non‐small‐cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited. This open‐label, multicenter, observational study evaluated real‐world the safety, efficacy, PK of pembrolizumab with NSCLC. In 99 aged ≥75 years, was determined by liquid chromatography–mass spectrometry pretreatment samples. Performance status (PS), geriatric assessment (GA), overall response rate (ORR),...
The treatment of lung cancer has made dramatic progress in the past decade, but due to high cost drugs, total pharmaceutical been rising explosively. There are currently no data available Japan on which regimens used, what extent they and their is.
Thymic epithelial tumors (TETs), which comprise thymoma and thymic carcinoma, are rare cancers with specific morphological clinical features. Their characteristics outcomes have gradually been clarified by assessing large-scale, retrospective data obtained international cooperation. The study is a review of 187 Japanese patients TETs who attended our institution from 1976 to 2012. Relevant features their tumors, including histology, staging, treatment strategies, overall survival, were...
Immuno-checkpoint inhibitor response and immune-related adverse events remain controversial issues. Managing pericardial effusion during programmed cell death 1 treatment is challenging. Here, we report a case of successfully managed cardiac tamponade caused by nivolumab-induced pseudoprogression. A 62-year-old male diagnosed with advanced lung adenocarcinoma started on nivolumab. Seven days later, he experienced required pericardiocentesis, other lesions were larger computed tomography. The...
The baseline tumor size (BTS) is a prognostic factor for patients with non-small cell lung cancer (NSCLC) who received immune checkpoint inhibitor monotherapy (ICI-mono). However, this relationship not yet known in treated ICI combination chemotherapy (ICI-chemo).
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC). Nevertheless, most cases ultimately acquire resistance to osimertinib, and no effective has been currently established having progressive disease (PD) with osimertinib. In clinical practice, EGFR-TKI therapy could be continued beyond response evaluation criteria in solid tumours...
8613 Background: Dual inhibition of the EGFR/VEGF pathways has demonstrated superior efficacy with 1st generation EGFR tyrosine kinase inhibitor (TKI) in patients non-small cell lung cancer (NSCLC) harboring mutations. This study aims to evaluate and safety combining osimertinib (Osi), a 3rd TKI considered standard care, ramucirumab (Ram). We have previously shown result progression free survival (PFS) as primary endpoint, median PFS was 20.0 months for Osi+Ram 24.0 Osi, hazard ratio 1.054...
Background: Because of the rarity thymic epithelial tumors (TETs), there is no treatment for managing unresectable that supported by a high level evidence. We present here clinical outcomes concurrent or sequential chemoradiotherapy patients with TETs. Methods: collated records 215 TETs who were treated at our institution and focused on 20 underwent without curative-intent surgical resection. Results: Six thymoma (4%) 14 carcinoma (19%) chemoradiotherapy. received therapy,...
Few studies have investigated the clinical efficacy of third- and later-line chemotherapy after standard for previously treated advanced non-small cell lung cancer (NSCLC). We prospectively evaluated safety nanoparticle albumin-bound paclitaxel (nab-paclitaxel) following chemotherapies NSCLC. The eligible patients having adequate organ functions with performance status 0–2 were enrolled completing chemotherapy. They received weekly nab-paclitaxel 100 mg/m2 intravenously on days 1, 8, 15...